Penumbra(US:PEN) Financial Modeling Prep·2026-01-16 03:02Core Viewpoint - Penumbra Inc. is set to be acquired by Boston Scientific Corp. in a deal valued at approximately $14.5 billion, which is expected to enhance Boston Scientific's portfolio in cardiovascular and neurovascular therapies [2][5] Group 1: Acquisition Details - Boston Scientific's acquisition offer values Penumbra at $374 per share, representing a 19% premium over its previous closing price [2][5] - The transaction will be financed with 73% cash and 27% stock, with Boston Scientific planning to fund the $11 billion cash portion through cash reserves and new debt [3] - Penumbra shareholders can choose between receiving $374 in cash or 3.87 shares of Boston Scientific stock [3] Group 2: Market Reactions - Following the acquisition announcement, Penumbra's shares surged nearly 12% to around $350, while Boston Scientific's shares declined by 4.5% to approximately $90 [4] - The boards of both companies have approved the transaction, which is expected to close in 2026, pending Penumbra shareholder approval [4] Group 3: Analyst Ratings - BTIG downgraded Penumbra from a Buy to a Neutral rating after the acquisition announcement, reflecting investor caution despite the premium offered [1][5]